Skip to main content

Advertisement

Table 1 Pharmacological characterization of PPAR induction of zebrafish fabp1a and fabp1b.1 promoter activity

From: Subfunctionalization of peroxisome proliferator response elements accounts for retention of duplicated fabp1 genes in zebrafish

fabp1a
  WY14643 Rosiglitazone
  - GW6471 T0070907 Δ5’FR ΔDR1 - GW6471 T0070907 Δ5’FR ΔDR1
E max (RLU) 152.80 ± 3.44 152.00 ± 7.80 147.90 ± 5.30 136.7 ± 11.1* 133.4 ± 4.94 152.80 ± 3.43 149.60 ± 3.66 151.70 ± 6.22 135.30 ± 7.11 144.40 ± 2.67
EC50 (μM) 0.26 (0.28–0.23) 15.7 (9.32–26.5)* 0.30 (0.20–0.44) 1.08 (0.71–6.70)* 11.9 (9.39–14.3)* 0.32 (0.30–0.34)*** 0.31 (0.24–0.41)*** 2.47 (1.59–3.83)**,*** 10.6 (2.67–4.19)** 31.8 (17.1–43.6)**,***
fabp1b.1
  WY14643 Rosiglitazone
  - GW6471 T0070907 Δ5’FR ΔDR1 - GW6471 T0070907 Δ5’FR ΔDR1
E max (RLU) 152.30 ± 5.57 151.30 ± 4.91 148.7 ± 5.27 146.4 ± 3.52 152.80 ± 7.24 152.30 ± 5.67 148.30 ± 4.87 150.70 ± 7.96 147.80 ± 2.02 178.50 ± 8.68**
EC50 (μM) 0.29 (0.17–0.49) 1.08 (0.86–1.54)* 0.10 (0.07–0.19) 0.67 (0.48–0.95) 28.8 (17.3–48.1)* 0.11 (0.07–0.15)*** 0.11 (0.08–0.15)*** 2.40 (1.39–4.15)**,*** 0.70 (0.56–0.89)** 54.5 (32.9–90.4)**
  1. Data derived from Figs. 4 and 5 presented as the mean ± SEM or 95 % confidence intervals (brackets)
  2. *P < 0.05 compared to WY14643 treatment alone within promoter
  3. **P < 0.05 compared to rosiglitazone treatment alone within promoter
  4. ***P < 0.05 rosiglitazone treatment compared to matched WY14643 treatment within promoter, as determined via two-way ANOVA followed by Bonferroni’s post-hoc analysis for E max, or by non-overlapping confidence intervals (EC50). n = 3